Merck KGaA (FRA:MRK) PT Set at €102.00 by Independent Research

Merck KGaA (FRA:MRK) received a €102.00 ($118.60) price objective from research analysts at Independent Research in a note issued to investors on Friday, Borsen Zeitung reports. The firm currently has a “neutral” rating on the healthcare company’s stock. Independent Research’s price target suggests a potential upside of 7.53% from the stock’s previous close.

Several other research analysts have also issued reports on MRK. Kepler Capital Markets set a €108.00 ($125.58) price target on shares of Merck KGaA and gave the stock a “buy” rating in a research report on Monday, June 17th. Morgan Stanley set a €96.00 ($111.63) price target on shares of Merck KGaA and gave the stock a “neutral” rating in a research report on Tuesday, June 18th. UBS Group set a €99.00 ($115.12) price target on shares of Merck KGaA and gave the stock a “neutral” rating in a research report on Thursday. Barclays set a €82.00 ($95.35) price target on shares of Merck KGaA and gave the stock a “sell” rating in a research report on Monday, May 27th. Finally, Nord/LB set a €94.00 ($109.30) price target on shares of Merck KGaA and gave the stock a “neutral” rating in a research report on Friday. One analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and five have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of €100.05 ($116.34).

Merck KGaA stock traded up €0.30 ($0.35) during mid-day trading on Friday, hitting €94.86 ($110.30). The company’s stock had a trading volume of 484,060 shares. Merck KGaA has a twelve month low of €76.60 ($89.07) and a twelve month high of €115.00 ($133.72). The firm’s fifty day simple moving average is €93.46.

About Merck KGaA

MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It offers prescription medicines to treat cancer, multiple sclerosis, infertility, growth deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, as well as squamous cell carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.

Recommended Story: Quiet Period Expirations

Analyst Recommendations for Merck KGaA (FRA:MRK)

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.